BMLOV
Latest Information Update: 17 Jan 2008
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Phosphoric monoester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Feb 2001 Profile reviewed but no significant changes made
- 01 Jul 1998 No-Development-Reported for Cancer in USA (Unknown route)
- 20 Sep 1995 Preclinical development for Cancer in USA (Unknown route)